Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol ED50 with low-dose sufentanil during hysteroscopic intravenous anesthesia
ChiCTR1900021224Phase 4Not yet recruiting
- Sponsor
- Chongqing Health Center for Women and Children
- Start
- Feb 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of propofol and sufentanil (2 arms), sponsored by Chongqing Health Center for Women and Children. Primary endpoint: Median effective dose. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
propofolsufentanil
Beyond the preview
Go deeper on ChiCTR1900021224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021224.